We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

65 hedge funds and large institutions have $40.1M invested in Palvella Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more call options, than puts

Call options by funds: $126K | Put options by funds: $18K

0.04% less ownership

Funds ownership: 0.63% → 0.59% (-0.04%)

4% less funds holding

Funds holding: 68 → 65 (-3)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

41% less capital invested

Capital invested by funds: $68.3M → $40.1M (-$28.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
5
Increased
13
Reduced
21
Closed
7
Calls
$126K
Puts
$18K
Net Calls
+$108K
Net Calls Change
-$90K

Top Buyers

1
ACM
Aquilo Capital Management
California
+$483K
2
LCM
Lynx1 Capital Management
Puerto Rico
+$470K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$385K
4
Renaissance Technologies
Renaissance Technologies
New York
+$243K
5
PIM
Platinum Investment Management
Australia
+$196K

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.93M
2
GPP
Great Point Partners
Connecticut
-$882K
3
Citigroup
Citigroup
New York
-$556K
4
XT
XTX Topco
Cayman Islands
-$186K
5
Millennium Management
Millennium Management
New York
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$124K – – –
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$123K -$56.1K -435 -25%
Citigroup
28
Citigroup
New York
$114K -$556K -4,311 -78%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$104K -$93.1K -722 -39%
6CM
30
683 Capital Management
New York
$104K – – –
Goldman Sachs
31
Goldman Sachs
New York
$74K -$23.9K -185 -19%
William Blair & Company
32
William Blair & Company
Illinois
$67K -$117K -907 -55%
BRWA
33
B. Riley Wealth Advisors
Florida
$60K +$83.2K +645 New
AC
34
Annandale Capital
Texas
$58K +$80.6K +625 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$46K -$3.22K -25 -5%
CIC
36
Cornercap Investment Counsel
Georgia
$45K – – –
WE
37
Wealth Effects
Massachusetts
$44K -$66.7K -517 -52%
Barclays
38
Barclays
United Kingdom
$43K – – –
Two Sigma Investments
39
Two Sigma Investments
New York
$43K +$60.9K +472 New
Charles Schwab
40
Charles Schwab
California
$42K – – –
NSEDCP
41
NJ State Employees Deferred Compensation Plan
New Jersey
$35K – – –
Franklin Resources
42
Franklin Resources
California
$35K +$516 +4 +1%
TRCT
43
Tower Research Capital (TRC)
New York
$25K +$34.4K +267 +8,900%
CB
44
Commerce Bank
Missouri
$23K – – –
RJA
45
Raymond James & Associates
Florida
$23K – – –
HSBC Holdings
46
HSBC Holdings
United Kingdom
$22K -$774 -6 -2%
NWA
47
Navis Wealth Advisors
New York
$18K – – –
Mackenzie Financial
48
Mackenzie Financial
Ontario, Canada
$16K – – –
VF
49
Virtu Financial
New York
$16K +$22K +171 New
Assenagon Asset Management
50
Assenagon Asset Management
Luxembourg
$14K -$1.93M -14,935 -99%
1
2
3

PVLA Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2022, worth a combined $40.1M — down 41% from $68.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PVLA and 5 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Aquilo Capital Management, adding an estimated $483K. The largest seller was Assenagon Asset Management, cutting an estimated $1.93M.

  • 65 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2022, down from 68 in Q2 2022.
  • Funds reported $40.1M of Palvella Therapeutics stock for Q3 2022, down 41% quarter-over-quarter.
  • 5 funds opened new Palvella Therapeutics positions in Q3 2022 and 7 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q3 2022 was Aquilo Capital Management, an estimated $483K added.
  • The largest Palvella Therapeutics seller in Q3 2022 was Assenagon Asset Management, an estimated $1.93M sold.

Based on aggregated 13F filings for Q3 2022.